Oxford BioMedica (LON:OXB)‘s stock had its “buy” rating restated by equities researchers at Liberum Capital in a research note issued on Wednesday, ThisIsMoney.Co.Uk reports.
Separately, Peel Hunt restated a “buy” rating on shares of Oxford BioMedica in a research note on Monday.
Shares of LON OXB opened at GBX 630.63 ($8.30) on Wednesday. Oxford BioMedica has a 1 year low of GBX 461.50 ($6.07) and a 1 year high of GBX 793 ($10.43). The stock has a market cap of $484.70 million and a P/E ratio of -54.36. The firm has a 50-day moving average of GBX 660.04 and a 200 day moving average of GBX 616.42. The company has a debt-to-equity ratio of 10.55, a current ratio of 2.21 and a quick ratio of 1.80.
About Oxford BioMedica
Oxford BioMedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various cancers, Parkinson's, central nervous system disorders, and ocular conditions in Europe and internationally. The company operates through Platform and Product segments.
Featured Article: What is Green Investing?
Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.